Brightseed Launches Enterprise AI Solution to Streamline Formulation and Manufacturing Success

Bioscience and artificial intelligence company Brightseed has launched the world’s first clinically validated enterprise artificial intelligence (AI) platform.¹ This new health sciences innovation is designed to integrate the discovery, development, and commercialization phases of product lifecycles into a unified architecture, to increase the probability of commercial success for health and life science organizations.

The launch addresses a critical bottleneck in the pharmaceutical and wellness industries, where over 75% of early product ideas fail to reach the market.¹ According to the company, these high failure rates are often the result of fragmented workflows, disconnected data sets, and the late-stage discovery of risks.¹

As AI continues to influence pharmaceutical commercialization and supply chain strategy, gaps can remain between early-stage scientific data and downstream decision-making. Insights related to sourcing, bioavailability, and formulation can surface late in the product lifecycle, limiting their impact on commercial planning. In response, platforms that aim to connect these stages are emerging as a way to improve alignment across development, manufacturing, and market access functions.

Brightseed’s new platform seeks to rebuild this model from the ground up. By connecting disparate stages of development, the system preserves scientific insight and decision context throughout the entire innovation lifecycle.¹ Lee Chae, PhD, co-founder and chief executive officer of Brightseed, noted in a release that health innovation has operated on a "broken probability curve" for decades.¹ Chae stated that the platform aims to fundamentally change that curve by defining a new category where AI serves as the core operating foundation of life sciences innovation rather than merely an "add-on".¹

What Are Brightseed’s Forager Discovery Engine and Data Assets?

At the heart of the platform lies Forager™, Brightseed’s proprietary AI discovery engine. This engine is built upon what the company describes as the world’s largest proprietary bioactive dataset, which spans more than 11 million natural compounds across 23 different health territories.¹

The company said that its platform utilizes proprietary biological intelligence designed for high scientific rigor, traceability, and defensibility.¹ This data-centric approach allows the company to transition from a discovery-focused bioactives firm into a platform-based enterprise AI company. The company is now delivering both data-as-a-service (DaaS) and software-as-a-service (SaaS) to global health science organizations.²

How Can Forager Optimize Manufacturing and Clinical Success?

A key feature of the platform is its ability to reduce challenges specifically related to formulation and manufacturing.² In an interview with Manufacturing Chemist, Brightseed explained that the platform supports critical decisions regarding bioavailability and sourcing. It achieves this by capturing and analyzing multi-omics data, such as Absorption, Distribution, Metabolism, and Excretion (ADME) predictions, as well as geographic origin and plant-part sourcing information within its extensive database.^1,2

The launch of this platform represents a significant evolution in Brightseed’s business model. The company spent more than four years working alongside over 40 industry-leading health science organizations. These partnerships, spanning consumer health, nutrition, pharmaceuticals, and animal health, provided the company with an end-to-end view of how innovation happens in practice.¹

Brightseed is now transitioning its customers to a recurring subscription model aligned with this platform-based strategy.¹ The company currently serves a $6.8 trillion global wellness market and is expanding its enterprise footprint as it enters its next phase of growth.¹ The multidisciplinary team behind the platform includes experts in biology, natural product chemistry, data science, and engineering.³

As part of its future roadmap, Brightseed is also developing agentic and workflow-driven capabilities, including emerging tools like Hummingbird, to support the full innovation lifecycle.³

References

1. Brightseed. Brightseed Launches the World’s First Clinically Validated, Enterprise AI Platform, Built on Over a Decade of Scientific Research [Internet]. South San Francisco (CA): Brightseed; 2026 Mar 25 [cited 2026 Mar 26]. Available from: https://www.brightseedbio.com/wp-content/uploads/2026/03/brightseed-platform-announcement-03252026-1.pdf
2. Brightseed launches AI-powered health sciences innovation platform. Manufacturing Chemist [Internet]. 2026 Mar 25 [cited 2026 Mar 26]. Available from: https://manufacturingchemist.com/brightseed-launches-ai-powered-health-sciences-innovation-platform?utm_source=chatgpt.com
3. Brightseed, Inc. Our Mission to Restore Human Health | Brightseed Bioactives [Internet]. Brightseed; 2026 [cited 2026 Mar 26]. Available from: https://www.brightseedbio.com/team/